{Reference Type}: Review
{Title}: Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines.
{Author}: Kim MJ;Moon JH;Lee EK;Song YS;Jung KY;Lee JY;Kim JH;Kim K;Park SK;Park YJ;
{Journal}: Endocrinol Metab (Seoul)
{Volume}: 39
{Issue}: 1
{Year}: 2024 02 15
{Factor}: 3.607
{DOI}: 10.3803/EnM.2024.1937
{Abstract}: The indolent nature and favorable outcomes associated with papillary thyroid microcarcinoma have prompted numerous prospective studies on active surveillance (AS) and its adoption as an alternative to immediate surgery in managing low-risk thyroid cancer. This article reviews the current status of AS, as outlined in various international practice guidelines. AS is typically recommended for tumors that measure 1 cm or less in diameter and do not exhibit aggressive subtypes on cytology, extrathyroidal extension, lymph node metastasis, or distant metastasis. To determine the most appropriate candidates for AS, factors such as tumor size, location, multiplicity, and ultrasound findings are considered, along with patient characteristics like medical condition, age, and family history. Moreover, shared decision-making, which includes patient-reported outcomes such as quality of life and cost-effectiveness, is essential. During AS, patients undergo regular ultrasound examinations to monitor for signs of disease progression, including tumor growth, extrathyroidal extension, or lymph node metastasis. In conclusion, while AS is a feasible and reliable approach for managing lowrisk thyroid cancer, it requires careful patient selection, effective communication for shared decision-making, standardized follow-up protocols, and a clear definition of disease progression.